期刊文献+

供者淋巴细胞输注在多发性骨髓瘤中的临床应用

原文传递
导出
摘要 供者淋巴细胞输注(DLI)作为一种过继免疫疗法,主要用于白血病在allo-SCT后的复发治疗,DLI在受者体内所介导的抗白血病效应(GVL)与输入的异基因免疫活性细胞诱导的免疫反应有关。近年来,逐渐有报道显示DLI在治疗多发性骨髓瘤allo-SCT后复发,以及增强移植物抗骨髓瘤(GVM)作用等方面具有巨大潜力。就DLI在MM治疗中的应用作一综述。供者淋巴细胞输注(DLI)作为一种过继免疫疗法,主要用于白血病在allo-SCT后的复发治疗,DLI在受者体内所介导的抗白血病效应(GVL)与输入的异基因免疫活性细胞诱导的免疫反应有关。近年来,逐渐有报道显示DLI在治疗多发性骨髓瘤allo-SCT后复发,以及增强移植物抗骨髓瘤(GVM)作用等方面具有巨大潜力。就DLI在MM治疗中的应用作一综述。
机构地区 中国医学科学院
出处 《白血病.淋巴瘤》 CAS 2005年第4期245-247,共3页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献17

  • 1Desikan R,Barlogie B,Sawyer J,et al.Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities [J].Blood,2000,95:4008-4010.
  • 2Bjorkstrand B B,Ljungman P,Svensson H,et al.Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective casematched study from the European Group for Blood and Marrow Transplantation[J].Blood,1996,88:4711-4718.
  • 3Martinelli G,Terragna C,Zamagni E,et al.Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation[J].Haematological,2000,85:930-934.
  • 4Kolb H J,Mittermuller J,Clemm C H,et al.Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients[J].Blood,1990,76:2462-2465.
  • 5Slavin S,Naparstek E,Nagler A,et al.Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes[J].Exp Hematol,1995,23:1553-1562.
  • 6Mthta J,Singhal S.Graft-versus-myeloma[J].Bone Marrow Transplant,1998,22:835-843.
  • 7Alyea E,Weller E,Schlossman R,et al.T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft- versus- myeloma effect [J].Blood,2001,98:934-939.
  • 8Lokhorst H M,Wu K,Verdonck L F,et al.The occurrence of graft- versus - host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma[J].Blood,2004,103:4362-4364.
  • 9Badros A,Barlogie B,Morris C,et al.High response rate in refractory and poor- risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [J].Blood,2001,97:2574-2579.
  • 10Ballester O F,Fang T,Raptis A,et al.Adoptive immunotherapy with donor lymphocyte infusions and interleukin - 2 after high - dose therapy and autologous stem cell rescue for multiple myeloma [J].Bone Marrow Tramsplant,2004,34:419-423.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部